Development and characterization of a cell donor registry for virus‐specific T cell manufacture in a blood bank

• DOI: 10.1111/tan.15419
• Publication Date: 2024-03-07T11:38:22Z
• Authors: Francesc Rudilla; María Paz Carrasc...; Helena Pasamar; María López‐Montañés; María Andrés‐Rozas; Maria Tomás‐Marín; Desirée Company; Cristina Moya; Luis Larrea; Manuel Guerreiro; Pere Barba; Cristina Arbona; Sergio Querol
• Keywords: Cytomegalovirus

Adoptive cell therapy using virus‐specific T cells (VST) is a strategy for treating common opportunistic viral infections after transplantation, particularly when these do not resolve through antiviral drug therapy. The availability of third‐party healthy donors allows the immediate use allogeneic in cases where patients lack an appropriate donor. Here, we present creation donor registry human leukocyte antigen (HLA)‐typed blood donors, REDOCEL, strategic initiative to ensure compatible donation needed. Currently, consists 597 with median age 29 years, 54% whom are women. most represented groups were A positive and O positive, 36.52% 34.51%, respectively. Also, screened cytomegalovirus (CMV) Epstein–Barr virus (EBV). Almost 65% CMV‐seropositive, while less than 5% EBV‐seronegative. Of CMV‐seropositive 98% also EBV‐seropositive. High‐resolution HLA‐A, ‐B, ‐C, ‐DRB1 ‐DQB1 allele haplotype frequencies determined registry. Prevalent HLA alleles haplotypes well donor‐recipient HLA‐matching, including reported immunodominant epitopes. Since functional establishment May 2019, 87 effective donations have been collected, first call has greater 75%. Thus, almost 89% receiving had available at least 5/10 HLA‐matched (HLA‐A, ‐DRB1, ‐DQB1). To summarize, based on our experience, from previously HLA‐typed useful tool facilitating access VST